Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M N Fleeton

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Vaccine|March 12, 1999
Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in miceP Berglund, M N Fleeton, C Smerdou, et al.
Nature Biotechnology|June 13, 1998
Enhancing immune responses using suicidal DNA vaccinesP Berglund, C Smerdou, M N Fleeton, et al.
The Journal of General Virology|February 17, 2000
Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccineM N Fleeton, P Liljeström, B J Sheahan, et al.
Gene Therapy|September 17, 2004
Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vectorJ W P Smyth, M N Fleeton, B J Sheahan, et al.
Gene Therapy|June 10, 2005
Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12C P Chikkanna-Gowda, B J Sheahan, M N Fleeton, et al.
The Journal of General Virology|June 4, 1999
Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challengeM N Fleeton, B J Sheahan, E A Gould, et al.
Oncology Reports|September 14, 2006
Inhibition of murine K-BALB and CT26 tumour growth using a Semliki Forest virus vector with enhanced expression of IL-18C P Chikkanna-Gowda, S McNally, B J Sheahan, et al.
Gene Therapy|December 15, 2006
Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in miceJ A Lyons, B J Sheahan, S E Galbraith, et al.
Vaccine|June 28, 2001
A recombinant Semliki Forest virus particle vaccine encoding the prME and NS1 proteins of louping ill virus is effective in a sheep challenge modelM M Morris-Downes, B J Sheahan, M N Fleeton, et al.
The Journal of Infectious Diseases|April 11, 2001
Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virusM N Fleeton, M Chen, P Berglund, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Vaccine|March 12, 1999
Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in miceP Berglund, M N Fleeton, C Smerdou, et al.
Nature Biotechnology|June 13, 1998
Enhancing immune responses using suicidal DNA vaccinesP Berglund, C Smerdou, M N Fleeton, et al.
The Journal of General Virology|February 17, 2000
Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccineM N Fleeton, P Liljeström, B J Sheahan, et al.
Gene Therapy|September 17, 2004
Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vectorJ W P Smyth, M N Fleeton, B J Sheahan, et al.
Gene Therapy|June 10, 2005
Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12C P Chikkanna-Gowda, B J Sheahan, M N Fleeton, et al.
The Journal of General Virology|June 4, 1999
Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challengeM N Fleeton, B J Sheahan, E A Gould, et al.
Oncology Reports|September 14, 2006
Inhibition of murine K-BALB and CT26 tumour growth using a Semliki Forest virus vector with enhanced expression of IL-18C P Chikkanna-Gowda, S McNally, B J Sheahan, et al.
Gene Therapy|December 15, 2006
Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in miceJ A Lyons, B J Sheahan, S E Galbraith, et al.
Vaccine|June 28, 2001
A recombinant Semliki Forest virus particle vaccine encoding the prME and NS1 proteins of louping ill virus is effective in a sheep challenge modelM M Morris-Downes, B J Sheahan, M N Fleeton, et al.
The Journal of Infectious Diseases|April 11, 2001
Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virusM N Fleeton, M Chen, P Berglund, et al.
Pageof 1